Revolution Medicines Receives 45 Million to Research Fungal Disease Treatment

REVOLUTION Medicines, located in the EnterpriseWorks incubator, has received a $45 million dollar investment from Third Rock Venture, a financing investment firm.  Although the initial goal is to find treatment for fungal disease, the hope is to find other disease treatments in the future as well.

REVOLUTION is the leading antifungal program at the University of Illinois Urbana-Champaign campus and has signed a license agreement stating exclusive rights to develop certain technology at the University. 

“Illinois has just created really powerful resources to allow that to happen, and so we’ve definitely benefited from that tremendously.” –Martin Burke, Head of REVOLUTION

Company Overview: 

REVOLUTION Medicines will develop a platform to rapidly open chemical space hereto inaccessible for drug development while enabling PhD chemists to focus on the utility of the molecules rather than the synthesis of the molecules.